pocketful logo
Anuh Pharma Ltd logo

Anuh Pharma Ltd

NSE: ANUHPHR BSE: 506260

₹78.25

(2.65%)

Wed, 18 Mar 2026, 06:30 am

mtf coin illustrationMTF 5x

Anuh Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    758.80

  • Net Profit

    47.35

  • P/B

    2.29

  • Sector P/E

    39.71

  • P/E

    15.75

  • EV/EBITDA

    10.38

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    20.07

  • ROCE (Industry)

    20.49

  • RONW (Industry)

    17.59

  • ROE

    13.41

  • ROCE

    17.15

  • Debt/Equity

    0.02

  • EPS (TTM)

    4.17

  • Dividend Yield

    0.99

  • Book Value

    32.62

  • Interest Cover

    43.86

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (3x coverage).
  • Anuh Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Anuh Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anuh Pharma is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Anuh Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • The level of debt compared to net worth has increased over the past 5 years (5.5% vs 6.3% today).
  • High level of physical assets or inventory.
  • Ritesh's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters71.8271.8269.9269.9269.92
FII0.000.000.040.040.02
DII0.000.000.000.000.00
Public28.1828.1830.0430.0530.06
Government00000

Read More

Technical Analysis

RSI

49.87

MACD

-0.24

50 DMA

76.90

200 DMA

86.63

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic106.6992.1184.6377.5370.0562.9548.37
Fibonacci92.1186.5483.1077.5371.9668.5262.95
Camarilla81.1779.8378.5077.5375.8274.4973.15

Pivots Level: Classic

R3

+29.16

106.69

R2

+14.58

92.11

R1

+7.11

84.63

77.53
77.53
Pivot Point
LTP: 77.22

S1

-7.47

70.05

S2

-14.58

62.95

S3

-29.16

48.37

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    76.95

  • 20-EMA

    77.18

  • 30-EMA

    77.30

  • 50-EMA

    77.66

  • 100-EMA

    79.57

  • 200-EMA

    83.61

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
06 Feb 2026board-meetingsQuarterly Results
07 Nov 2025board-meetingsQuarterly Results
15 Jul 2025dividendFinal Dividend - Rs. - 1.515 Aug 2025
14 Jul 2025dividendDividend - Rs 1.50 Per Share15 Aug 2025
09 Jul 2025bonus1:1 Bonus Issue of Equity Shares15 Jul 2025
15 Jun 2025bonusBonus issue 1:115 Jul 2025
23 May 2025dividend₹1.50 Dividend /Share15 Aug 2025
23 May 2025agm
17 May 2024dividend₹2.50 Dividend /Share16 Aug 2024
17 May 2024agm

Read More

Peer Comparison

Anuh Pharma Ltd logo

Anuh Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Anuh Pharma Ltd About

Anuh Pharma is engaged in the business of manufacturing and selling of “Bulk drugs and chemicals.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1960

Headquarters

CEO

Arun Todarwal

Employees

Contact

Website icon

Website

http://www.anuhpharma.com

Email icon

Email

anuh@sk1932.com

Phone icon

Phone

91-22-6622 7575

Location icon

Location

3-A Shivsagar Estate, North Wing Dr A B Road Worli, Mumbai, Maharashtra, 400018

Read More

Anuh Pharma Ltd Company History

YearHistory
2013
  • Anuh Pharma has recommended a dividend of Rs. 6.00 per equity share of face value of Rs. 5.00.
2014
  • Anuh Pharma Ltd have received approval from COFEPRIS (Health Authority of Mexico) GMP certificate for three of Companys Erythromycin products
  • Anuh Pharma has recommended a Final Dividend of Rs. 6.50 (130%) per share.
2015
  • The Company has allotted the Bonus Shares to its shareholders in the Ratio of 2:1.
2016
  • Anu Pharma Ltd has received EUGMP Certificate granted by ANSM - France.
2020
  • The Company has issued Bonus Shares in the Ratio of 1:1.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
KETAN LALIT SHAHSell145700196.6229 Sept 2020
LALIT POPATLAL SHAHBuy69404676.2807 May 2015
KETAN LALIT SHAHBuy76900675.0307 May 2015
L P SHAH HOLDINGS AND TRADES LLPSell184804675.0207 May 2015
BHARAT NEMCHAND SHAHSell16000559.7520 Aug 2010
MRUDULA JAYANTILAL SHAHBuy16000559.7520 Aug 2010
SAMIR JAYANTILAL SHAHBuy15856322.516 Nov 2009
PRAFULLA LALITKUMAR SHAHSell27000232.915 Sept 2008
L P SHAH HOLDING TRADES PVT LTDBuy27000232.915 Sept 2008
RELIANCE CAP TRU CO LTD ASell82072667.4524 Apr 2006

Read More

Anuh Pharma Ltd News

Anuh Pharma Clears EDQM Audit at Manufacturing Units

Anuh Pharma Limited successfully passes European Directorate for Quality of Medicines audit at its Tarapur manufacturing facilities, reaffirming global regulatory compliance standards.

06 Mar 2026

stocks

Anuh Pharma Reports Strong Q3FY26 Financial Results

Anuh Pharma Limited published unaudited financial results for Q3FY26, showing revenue of ₹19,717.81 lakhs and net profit of ₹1,345.10 lakhs with improved margins.

08 Feb 2026

co actions results

Anuh Pharma faces ₹78.29L tax demand for AY 2020-21

Anuh Pharma Limited receives Income Tax Assessment Order with tax demand of ₹78,28,793 for Assessment Year 2020-21 due to disallowed deductions. Company plans to file appeal.

21 Jan 2026

stocks

Anuh Pharma Receives European Certificate of Suitability for Sulfadimethoxine

Anuh Pharma Limited has been granted the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines HealthCare (EDQM) for Sulfadimethoxine. The CEP approval will enable expanded access to regulated markets and support customers with enhanced reliability, compliance, and supply security for this Active Pharmaceutical Ingredient.

05 Dec 2025

stock

Anuh Pharma Projects 15-16% Annual Growth Rate

Anuh Pharma has announced expectations for an annual growth rate ranging between 15% and 16%. The pharmaceutical company's growth projection indicates anticipated business expansion in its operations.

17 Nov 2025

stock

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800